A case report presents a patient with progressive drusen accumulation, which was halted by a resveratrol-based nutraceutical (Longevinex). The patient's vision improved after adopting the nutraceutical regimen, whereas statin drugs showed only modest success. A dietary approach to retinal health is proposed as primary consideration.
A nutraceutical called Longevinex has been shown to reduce the time it takes for older eyes to adapt to the dark, predicting future onset of macular degeneration. The study found that 12 out of 14 eyes tested improved or were stable after using Longevinex.
Researchers have confirmed that resveratrol metabolites can be detected in ocular tissues, including the conjunctiva and aqueous fluid. This finding opens up new avenues for exploring the therapeutic potential of resveratrol in human eye health.
Researchers report a breakthrough treatment for invasive macular degeneration, using an oral nutriceutical that rapidly restores vision and improves overall eye health. In 16 successful cases, the treatment showed significant improvements in visual acuity, contrast vision, and circulatory health within 3-6 weeks.
Early data suggests molecular medicine can restore normal retina architecture and improve visual function in severe cases of macular degeneration. Researchers are now calling for larger human trials to validate the approach's reliability and safety.
Researchers found Longevinex, a resveratrol supplement, provides cardio-protection across a wide dosage range without toxic effects. Unlike plain resveratrol, Longevinex exhibits an L-shaped safety curve, minimizing heart damage and optimizing protection.
A recent study published in PLoS ONE found that Longevinex exerts a greater influence on genes than resveratrol, leading to improved heart health outcomes. The research demonstrated that Longevinex reduced the size of heart attacks and protected against cell death, while also improving microRNA activity.